logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Successful results were announced by uniQure for its gene therapy, AMT-061, on hemophilia B patients

The United States FDA granted Breakthrough Therapy Designation to AMT-061. The European Medicines Agency gave it access to the Priority Medicine (PRIME) regulatory initiative. Gene therapy firm,  uniQure ( QURE ),  announced updated clinical data in patients treated in the...

Read More

February 11, 2019

0

Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients

Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...

Read More

July 1, 2020

0

CRISPR Therapeutics and Sisters

CRISPR, Intellia and Editas CRISPR Therapeutics ( CRSP ) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large...

Read More

February 13, 2020

0

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

RegenxBio ( RGNX ) ,  a clinical-stage gene therapy firm with a proprietary NAV ®  Technology Platform, will host an analyst and investor event focused on its ophthalmology program;  including its lead product candidate RGX-314 , on Thursday, February 21, 2019, from 9:00...

Read More

February 15, 2019

0

Biotech Stocks Expected to Outperform in Today's Tumbling Market

Gilead and Moderna Stocks Will Outperform Today As stated in Prohost Letter #439 Gilead ( GILD ) investigational product remdesivir has offered hope towards treating infected people with COVID-19 . Regarding the possibility of rapidly designing, creating and developing a...

Read More

February 24, 2020

0

Merck's product Keytruda and Exelixis' product Cabometyx are both winners

Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 trial The pivotal Phase 3 KEYNOTE-240 trial evaluating Keytruda, Merck’s ( MRK ) checkpoint inhibitor anti-PD-1 therapy plus best supportive care, for the treatment...

Read More

February 21, 2019

0

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91 

We congratulate our subscribers who kept  Spark Therapeutics ( ONCE ) in spite of the stock’s kind of paralysis for no serious reasons. Spark, a fully integrated, commercial gene therapy company, announced today that it has entered into a definitive merger agreement...

Read More

February 25, 2019

0

INmune Bio: A Novel Approach Towards Treating Alzheimer's Disease

Alzheimer's Disease Alzheimer’s Disease has proven very difficult to treat through many of the trials’ attempts by both small and large biotechnology and biopharmaceutical companies. Analysts and investors are skeptical about all promised successes in defeating this disease. However,  knowing...

Read More

July 14, 2020

0

Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

Gilead Sciences to Acquire Forty Seven Gilead Sciences ( GILD ) and  Forty Seven ( FTSV ) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash ....

Read More

March 2, 2020

0

Jazz Pharmaceuticals: A New FDA Approval

People living with narcolepsy who develop cataplexy and excessive daytime sleepiness have a new treatment called Xywav, from Jazz Pharmaceuticals. Jazz Pharmaceuticals NEWS On July 21, 2020 the U.S. FDA approved Jazz Pharmaceuticals’ ( JAZZ ) product Xywav™ (calcium, magnesium, potassium...

Read More

July 22, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 79
  • 80
  • 81
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy